- Home
- WTI vs CRVS Comparison
WTI vs CRVS Comparison
Compare WTI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WTI
- CRVS
- Stock Information
- Founded
- WTI 1983
- CRVS 2014
- Country
- WTI United States
- CRVS United States
- Employees
- WTI N/A
- CRVS N/A
- Industry
- WTI Oil & Gas Production
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- WTI Energy
- CRVS Health Care
- Exchange
- WTI Nasdaq
- CRVS Nasdaq
- Market Cap
- WTI 172.8M
- CRVS 206.5M
- IPO Year
- WTI 2005
- CRVS 2016
- Fundamental
- Price
- WTI $1.17
- CRVS $3.63
- Analyst Decision
- WTI
- CRVS Strong Buy
- Analyst Count
- WTI 0
- CRVS 3
- Target Price
- WTI N/A
- CRVS $15.67
- AVG Volume (30 Days)
- WTI 1.6M
- CRVS 906.6K
- Earning Date
- WTI 05-06-2025
- CRVS 05-05-2025
- Dividend Yield
- WTI 3.42%
- CRVS N/A
- EPS Growth
- WTI N/A
- CRVS N/A
- EPS
- WTI N/A
- CRVS N/A
- Revenue
- WTI $525,260,999.00
- CRVS N/A
- Revenue This Year
- WTI $3.79
- CRVS N/A
- Revenue Next Year
- WTI N/A
- CRVS N/A
- P/E Ratio
- WTI N/A
- CRVS N/A
- Revenue Growth
- WTI N/A
- CRVS N/A
- 52 Week Low
- WTI $1.09
- CRVS $1.43
- 52 Week High
- WTI $2.84
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- WTI 36.02
- CRVS 55.04
- Support Level
- WTI $1.13
- CRVS $3.15
- Resistance Level
- WTI $1.20
- CRVS $3.78
- Average True Range (ATR)
- WTI 0.08
- CRVS 0.25
- MACD
- WTI 0.01
- CRVS 0.12
- Stochastic Oscillator
- WTI 29.55
- CRVS 87.90
About WTI W&T Offshore Inc.
W&T Offshore Inc is an oil and gas exploration and production company. The company's exploration operations are focused in the Gulf of Mexico, where it drills for oil and gas. The company engages in both deepwater drilling and shallow-water shelf drilling. W&T Offshore extracts crude oil, natural gas, and natural gas liquids, which are then sold directly at the wellhead. Overall, crude oil accounts for the majority of company's revenue, with natural gas accounting for a much smaller portion.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).